Amendments to the Claims:

The following listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1-5. (Canceled)

6. (Currently Amended) A composition[[,]] comprising a therapeutically effective amount of the molecule of claim 48 and at least one pharmaceutically acceptable carrier.

7. (Currently amended) A composition[[,]] comprising a therapeutically effective amount of an immunoglobulin according to claim 48 that binds to A34 and is conjugated to an anti-cancer agent, and at least one pharmaceutically acceptable carrier.

8-24. (Canceled)

25. (Previously presented) The immunoglobulin molecule of claim 48, wherein said immunoglobulin molecule is humanized.

26. (Previously presented) The immunoglobulin molecule of claim 48, wherein said immunoglobulin molecule is fully human.

27. (Previously presented) The immunoglobulin molecule of claim 48, wherein said immunoglobulin molecule is recombinant.

28. (Previously presented) An immunoglobulin molecule according to claim 48 that binds to A34 and is conjugated to at least one anti-cancer agent.

29. (Previously presented) The immunoglobulin molecule according to claim 28, wherein said anti-cancer agent is selected from the group consisting of radioisotopes, chemotherapeutic agents, cytotoxic agents and combinations thereof.

30. (Previously presented) The immunoglobulin molecule according to claim 29, wherein said anti-cancer agent is a radioisotope selected from the group consisting of ^{125}I, ^{131}I, ^{99}Tc, ^{90}Y and ^{111}In.

31. (Previously presented) The immunoglobulin molecule according to claim 28, wherein said anti-cancer agent comprises a chemotherapeutic agent or cytotoxic agent selected from the group consisting of QFA, antifolates, BCNU (carmustine), mercaptopurine, methotrexate, docetaxel, adriamycin, calicheamicin cellular toxin, bacterial toxin, pseudomonas exotoxin, ricin, diptheria toxin and combinations thereof.

32-34. (Canceled)

35. (Currently amended) The substantially pure immunoglobulin molecule according to claim 48, ~~where~~ wherein the immunoglobulin molecule binds to an extracellular portion of A34.

36-46. (Canceled)

47. (Previously presented) A substantially pure immunoglobulin molecule which binds specifically to A34 antigen, wherein said immunoglobulin molecule comprises:

at least one heavy chain variable region selected from SEQ ID NO: 23, SEQ ID NO: 27, and SEQ ID NO: 31; and

at least one light chain variable region selected from SEQ ID NO: 21, SEQ ID NO: 25, and SEQ ID NO: 29.

48. (Currently amended) A substantially pure immunoglobulin molecule which binds specifically to A34 antigen wherein said immunoglobulin molecule comprises: ~~at least one light chain variable region and at least one heavy chain variable region, wherein said heavy chain variable region comprises a CDR3 region consisting of the sequence of SEQ ID NO: 37 or SEQ ID NO: 49~~

1) at least one light chain variable region comprising a CDR1 region consisting of a sequence selected from SEQ ID NO: 32, SEQ ID NO: 38 and SEQ ID NO: 44; a CDR2 region consisting of the sequence of SEQ ID NO: 33 or SEQ ID NO: 45; and a CDR3 region consisting of the sequence of SEQ ID NO: 34 or SEQ ID NO: 46; and

2) at least one heavy chain variable region comprising a CDR1 region consisting of a sequence selected from SEQ ID NO: 35, SEQ ID NO: 41 and SEQ ID NO: 47; a CDR2 region consisting of the sequence of SEQ ID NO: 36 or SEQ ID NO: 48; and a CDR3 region consisting of the sequence of SEQ ID NO: 37 or SEQ ID NO: 49.

49-71. (Canceled)

72. (Currently amended) A composition[[,]] comprising a therapeutically effective amount of the molecule of claim 47 and at least one pharmaceutically acceptable carrier.

73. (Currently amended) A composition[[,]] comprising a therapeutically effective amount of an immunoglobulin according to claim 46 that binds to A34 and is conjugated to an anti-cancer agent, and at least one pharmaceutically acceptable carrier.

74. (Previously presented) The immunoglobulin molecule of claim 47, wherein said immunoglobulin molecule is humanized.

75. (Previously presented) The immunoglobulin molecule of claim 47, wherein said immunoglobulin molecule is fully human.

76. (Previously presented) The immunoglobulin molecule of claim 47, wherein said immunoglobulin molecule is recombinant.

77. (Previously presented) An immunoglobulin molecule according to claim 47 that binds to A34 and is conjugated to at least one anti-cancer agent.

78. (Previously presented) The immunoglobulin molecule according to claim 77, wherein said anti-cancer agent is selected from the group consisting of radioisotopes, chemotherapeutic agents, cytotoxic agents and combinations thereof.

79. (Previously presented) The immunoglobulin molecule according to claim 78, wherein said anti-cancer agent is a radioisotope selected from the group consisting of ^{125}I, ^{131}I, ^{99}Tc, ^{90}Y and ^{111}In.

80. (Previously presented) The immunoglobulin molecule according to claim 77, wherein said anti-cancer agent comprises a chemotherapeutic agent or cytotoxic agent selected from the group consisting of QFA, antifolates, BCNU (carmustine), mercaptopurine, methotrexate, docetaxel, adriamycin, calicheamicin cellular toxin, bacterial toxin, pseudomonas exotoxin, ricin, diptheria toxin and combinations thereof.

81. (Currently amended) The substantially pure immunoglobulin molecule according to claim 47, ~~where~~ wherein the immunoglobulin molecule binds to an extracellular portion of A34.